BioCryst Pharmaceuticals
| Type | Public |
|---|---|
| Nasdaq: BCRX Russell 2000 Component | |
| Industry | Healthcare |
| Founded | 1986 |
| Headquarters | Durham, North Carolina, US |
| Key people | Charlie Gayer (president and CEO) |
| Products | ORLADEYO, RAPIVAB |
| Revenue | |
Number of employees | 450 |
| Website | www.biocryst.com |
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.